Voyager Therapeutics (VYGR) Interest Expenses (2014 - 2016)

Voyager Therapeutics has disclosed Interest Expenses across 3 years of filings, most recently posting -$283000.0 for Q2 2016.

• Interest Expenses for Q2 2016 came in at -$283000.0, down 293.06% year-over-year; the trailing twelve-month figure through Mar 2017 was -$283000.0 (up 63.95% YoY), and the FY2015 annual result was $9.4 million, up 383.22% from the prior year.
• Interest Expenses came in at -$283000.0 for Q2 2016 at Voyager Therapeutics, down from -$279000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $9.7 million in Q1 2015 to a low of -$332000.0 in Q4 2015.
• The 3-year median for Interest Expenses is -$87000.0 (2015), against an average of $1.2 million.
• Peak annual rise in Interest Expenses reached 102.86% in 2016, while the deepest fall reached 293.06% in 2016.
• Voyager Therapeutics' Interest Expenses stood at $195000.0 in 2014, then slumped by 270.26% to -$332000.0 in 2015, then advanced by 14.76% to -$283000.0 in 2016.
• The last three Interest Expenses figures came in at -$283000.0 (Q2 2016), -$279000.0 (Q1 2016), and -$332000.0 (Q4 2015), per Business Quant data.